SuperworthMonte Rosa Therapeutics price to sales ratio GLUE
Market value divided by revenue over the last twelve months, since 2025.
- Today, Oct 23, 2026
- 32.2×
- Peer median
- 4.7×
Monte Rosa Therapeutics' price to sales ratio is 32.2× as of Oct 23, 2026.
The median for 5 biotech stocks of a similar size is 4.7×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 32.2× | 5.5× | 48.3× |
| 2025 | 6.2× | 1.5× | 6.2× |
Against its peers
Companies in Biotechnology nearest Monte Rosa Therapeutics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| GLUEMonte Rosa Therapeutics | 32.2× |
| MGTXMeiraGTx | 2.2× |
| VCELVericel | 7.1× |
| ADMAAdma Biologics | 4.7× |
| PLXProtalix BioTherapeutics | 2.5× |
| KRYSKrystal Biotech | 20.9× |
| Peer median | 4.7× |
Where Monte Rosa Therapeutics ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Monte Rosa Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.